Key result
Medical management of Eisenmenger's syndrome is rapidly evolving with therapies such as phosphodiesterase inhibitors, endothelin receptor antagonists, and prostanoids, making transplantation less likely.
This review highlights the evolving medical management of Eisenmenger's syndrome, including the use of phosphodiesterase inhibitors, endothelin receptor antagonists, and prostanoids, which may reduce the need for transplantation.
Advanced therapies may reduce transplantation need in Eisenmenger syndrome; leaves open long-term outcome comparisons with historical data.
The number of children with congenital heart disease graduating to adult care is increasing rapidly as treatment becomes more successful. A significant proportion has pulmonary hypertension, which will lead to Eisenmenger’s syndrome, having an associated high morbidity and mortality rate. This article discusses the pathophysiology of Eisenmenger’s syndrome, its clinical course and management. Medical management of these complex patients is evolving quickly and rapidly changing. We discuss each of the therapies available for the treatment of this disease, use of phosphodiesterase inhibitors, endothelin receptor antagonists and prostanoids. Transplantation is now less likely with these new medications. We also discuss the important role of the nurse in Eisenmenger’s syndrome and administration of various therapies.
No takes yet. Share an insight, caveat, or question.
Bradford et al. (2008) conducted a review in Eisenmenger's syndrome. Medical management (phosphodiesterase inhibitors, endothelin receptor antagonists, prostanoids) was evaluated. Medical management of Eisenmenger's syndrome is rapidly evolving with therapies such as phosphodiesterase inhibitors, endothelin receptor antagonists, and prostanoids, making transplantation less likely.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: